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Abstract
Background: Teleconsultation seems to be a promising intervention for providing palliative care to home-dwelling
patients; however, its effect on clinically relevant outcome measures remains largely unexplored. Therefore, the
purpose of this study was to determine whether weekly teleconsultations from a hospital-based specialist palliative
care consultation team (SPCT) improved patient-experienced symptom burden compared to “care as usual”. Secondary
objectives were to determine the effects of these teleconsultations on unmet palliative care needs, continuity of care,
hospital admissions, satisfaction with teleconsultations, and the burden experienced by informal caregivers.
Methods: Seventy-four home-dwelling patients diagnosed with advanced cancer were recruited from outpatient
clinics of a tertiary university hospital and from regional home care organizations between May 2011 and January 2015.
Participants were randomized to receive weekly, prescheduled teleconsultations with an SPCT-member (intervention
group), or to receive “care as usual” (control group), for a period of 12 weeks. The primary outcome of this study was:
patient-experienced symptom burden indicated by the following: (1) Total Distress Score (defined as the sum of all
nine subscales of the Edmonton Symptom Assessment System) and (2) the Hospital Anxiety and Depression Scale.
Mixed models were used to test for differences between the two groups.
Results: The Total Distress Score became significantly higher in the intervention group than in the control group,
reaching significance at week 12 (adjusted difference at week 12: 6.90 points, 95% CI, 0.17 to 13.63; P = 0.04). The
adjusted anxiety scores were higher in the intervention group than in the control group (estimate effect: 1.40; 95% CI,
0.14 to 2.55; P = 0.03). No difference was found between the groups in adjusted depression scores (estimate effect: 0.30;
95% CI, −1.39 to 1.99; P = 0.73) or in secondary outcome measures.
Conclusions: Adding weekly teleconsultations to usual palliative care leads to worse reported symptom scores among
home-dwelling patients with advanced cancer. Possible explanations for these findings include excess attention on
symptoms and (potential) suffering, the supply-driven care model for teleconsultations used in this trial, and the
already high level of specialist palliative care provided to the control group in this study.
Trial registration: “The Netherlands National Trial Register”, NTR2817, prospectively registered: March 21, 2011.
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Background
Palliative care intends to improve the quality of life of pa-
tients facing life-threatening illnesses and that of their
families [1]. Due to an increase in the number of patients
dying from chronic, life-threatening conditions, the need
for palliative care is expected to rise [2, 3]. In the
Netherlands, as well as in other Western countries, the
majority of these patients prefer to be cared for at home
until death [4, 5]. An important condition for dying at
home is the availability of easily accessible, community-
based palliative home care [6–9]. Consequently, general
practitioners (GPs) play a vital role in the delivery of
palliative care to home-dwelling patients [8, 10].
However, when a patient’s condition deteriorates, pallia-
tive care can become increasingly complex [11]. As a result,
GPs may require additional expertise [12–14]. Sustainable
models for collaboration between GPs and expert palliative
care teams should therefore be developed to guarantee pro-
active, continuous, yet patient-centered palliative home
care. Telemedicine might be an innovative approach to
supporting these collaborations [15].
One of the applications of telemedicine is videoconfer-
encing (also video- or teleconsultations), which involves the
use of real-time (synchronous) audio-visual communication
technology [16]. Videoconferencing has been proven to be
feasible, acceptable, and effective in different fields of
medicine, including psychiatry, diabetes care, and oncology
[17–20]. Within palliative care, videoconferencing tech-
niques have been used to establish multidisciplinary meet-
ings between (rural) health centers and specialized
institutes, to support patients and their families in their
home-environment, and to deliver hospice care to patients
living at a distance [21–26]. The results regarding the use
of these techniques in palliative care are promising in terms
of feasibility, acceptance and satisfaction among its users,
cost-efficacy, and quality of care [22–27].
Although these results are promising, studies describing
the use of videoconferencing techniques to improve the
quality of palliative care for patients residing at home are
generally small or have methodological limitations [16].
Recent reviews on this topic emphasize the need for
randomized clinical trials (RCTs) with clinically relevant
outcomes that are measured with validated instruments
[16, 28–30].
Therefore, the primary objective of this study was to
evaluate whether weekly teleconsultations between patients
receiving palliative home care and a hospital-based
specialist palliative care consultation team (SPCT) improves
patient-experienced symptom burden when compared to
“care as usual”.
The secondary objectives were to evaluate the effect of
these teleconsultations on (1) unmet palliative care needs,
(2) experienced continuity of medical care, (3) hospital
admissions, and (4) satisfaction with teleconsultations.
Furthermore, the effect of teleconsultations on the burden
experienced by informal caregivers, as well as healthcare
professionals’ satisfaction with teleconsultations, were
evaluated.
Methods
Design
We conducted a two-armed, non-blinded randomized clin-
ical trial. The study protocol (Reg 2010/382) was approved
by the Committee on Research Involving Human Subjects
Region Arnhem-Nijmegen and has been previously pub-
lished [15]. The study was prospectively registered at The
Netherlands National Trial Register (NTR2817). During
the study period, two amendments were approved by the
Committee on Research Involving Human Subjects. Writ-
ten informed consent was obtained from all participants.
Participants
Setting and location
Initially, the inclusion period for this trial was 18 months.
However, mainly as a result of recruitment delay, the inclu-
sion period was extended to 45 months (May 2011–January
2015). Patients were recruited from the outpatient clinics of
the Radboud university medical center, Nijmegen, the
Netherlands, mainly at the Department of Palliative Medi-
cine as well as from regional home care organizations.
Inclusion criteria
Participants had to be aged 18 years or above, Dutch speak-
ing, and able to give informed consent. Furthermore, they
initially had to meet the following criteria: (1) be diagnosed
with a progressive oncological condition, (2) reside at
home, (3) have a GP who agrees to participate, (4) have a
Karnofsky Performance Status score (KPS) of 60 or below,
and (5) have a life-expectancy of 3 months or less.
Because of recruitment problems, the first amendment
was implemented in February 2013, after 24 participants
had been included. The criteria of a KPS of 60 or below
and life expectancy of 3 months or less were replaced by a
new criterion, namely that patients should not be receiving
any disease-modifying treatment at the time of inclusion
nor would do so in the future. However, as recruitment did
not improve sufficiently, a second amendment was imple-
mented in July 2013, after 35 participants had been
included, whereby the latter criterion was removed and was
not replaced with new inclusion criteria.
Randomization
After completing the baseline measurements, the partici-
pants were randomized into two groups: intervention or
control. We used block randomization with different size
blocks (4 and 6) to maintain an equal balance between
groups. Randomization occurred at the level of individ-
ual patients, with an allocation ratio of 1:1. The author
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involved in the process of approaching, informing and
visiting participants (PH) was not informed about the
outcome of the randomization process before baseline
measurements had taken place.
Initially, it was expected that patients would be recruited
by their GPs and therefore, to prevent bias, a cluster
randomization procedure at the level of the GP was
described in the original study protocol [15]. However, the
vast majority of patients were eventually recruited via the
SPCT and GPs did not recruit individual participants for
this study. Consequently, there were no clusters of partici-
pants with the same GP. Therefore, in the first amendment,
we decided that there was no further need for cluster
randomization. As a result, randomization took place at the
level of the individual participant.
Care as usual
Participants in both groups received palliative home care
provided by their GP, supported by the SPCT according
to the standard referral procedures, i.e., patients could
be referred to the SPCT by their GP or by the attending
hospital specialist or were not referred at all. If applic-
able, follow-up by the SPCT occurred by phone or by
patients visiting the outpatient clinic, depending on the
patient’s preference, the complexity of their problems,
and/or the stage of their disease.
Intervention group
Procedure
Participants in the intervention group had weekly telecon-
sultations for a period of 13 weeks in addition to their usual
care. First, a teleconsultation device was installed at the pa-
tient’s home. Patients who had not visited the SPCT before
were evaluated at the outpatient clinic or during a home
visit by one of the SPCT members (a nurse or physician).
Then, teleconsultations were scheduled on a weekly basis
for a period of 13 weeks. At the agreed time, a member of
the SPCT (mostly the nurse practitioner) initiated the tele-
consultation. In between these scheduled appointments,
the participants could not directly contact the SPCT mem-
bers through teleconsultation. When in need of medical
advice, the patients were encouraged to contact their GP;
however, if necessary, the SPCTcould be reached by phone.
A predefined consultation schedule was available to the
SPCT members to ensure that all domains of palliative care
were sufficiently covered during the teleconsultations.
Problems and needs of participants were identified and
discussed with other team members if necessary. The
participant’s GP was invited to visit and join the patient
during the teleconsultation appointments. If this was not
possible, after the first teleconsultation, a member of the
SPCT contacted the patient’s GP by phone to discuss the
patient’s current problems and needs, possible treatment
policies, and the GP’s involvement during the following
study period. After the first and the last scheduled telecon-
sultation, the SPCT was encouraged to send a letter to the
participant’s GP, outlining the patient’s current problems
and needs and advised treatment policies.
Teleconsultation device
Initially, in 2011, teleconsultation devices consisted of a
Pal4-desktop computer (“Bidibox”, Focuscura Inc., the
Netherlands) with a touch screen, a separate microphone/
speaker, and a separate camera. During the study period,
tablet computers became available. These devices seemed
more user-friendly, and therefore the “Bidibox” computers
were replaced by tablet computers (iPad 2® and iPad mini®;
Apple Inc., United States). The Pal4 application was
replaced by FaceTime® (Apple Inc., United States).
Outcome measures
The primary outcome was patient-experienced symptom
burden, based on the Edmonton Symptom Assessment
System (ESAS) and the Hospital Anxiety and Depression
Scale (HADS). The secondary and other study outcomes
have been described in our study protocol [15].
Data collection
Data collection ended after 12 weeks. During the 13th week
of the study period a closing teleconsultation was scheduled
for participants from the intervention group. During this
13th week participants did not complete any questionnaires.
Questionnaires for baseline measurements were handed
over by one of the researchers (PH) or sent through postal
mail. After completion, participants handed over the ques-
tionnaires to the researchers or sent them back through
postal mail. During the study period, participants received
and returned the required questionnaires through postal
mail and sent them back every 4 weeks. If necessary, one of
the researchers (PH) reminded the participants by phone,
SMS, or e-mail to return the required questionnaires.
Participants completed the following questionnaires: the
ESAS (at baseline, weekly follow-up), HADS, Problems and
Needs in Palliative Care-short version, and a modified
version of the Nijmegen Continuity Questionnaire (NCQ)
(all three: at baseline, four-weekly follow-up). Informal
caregivers completed one questionnaire: Self-Perceived
Burden from Informal Care (EDIZ) (at baseline, two-weekly
follow-up).
Additionally, participants in the intervention group com-
pleted a Patient Satisfaction Questionnaire (PSQ) after the
first two teleconsultations. If applicable, the SPCT members
involved in the teleconsultations and the participant’s GPs
also completed a PSQ after the first two teleconsultations.
Finally, demographic information was collected at base-
line. Information on other study outcomes (GP contacts,
complex interventions, and hospital admissions [15]) was
requested from the patient’s GP after the study period.
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Questionnaires
The ESAS is a self-reporting scale consisting of nine
symptoms that are common in patients diagnosed with
cancer [31]. Items can be scored on a 0–10 visual numer-
ical scale (with 0 indicating the absence of a symptom and
10 indicating the worst imaginable intensity of a symptom).
The ESAS is widely used, and its psychometric properties
are considered good in our study population [32–35]. The
Total Distress Score (TDS) is defined as the sum of the
nine subscales. The HADS is a 14-item self-report
screening scale that provides an indication of the possible
presence of anxiety and depressive symptoms [36]. Each
item is scored on a 4-point Likert scale. The questions
assess symptoms in the preceding week. Its psychometric
properties are considered moderate to good [35, 37].
The secondary outcomes of this study were measured
by the following questionnaires: (1) the Problems and
Needs in Palliative Care-short version (patient-experienced
problems and needs) [38, 39], (2) the NCQ (patient-
experienced continuity of care) [40, 41], (3) the PSQ
(satisfaction with teleconsultations) [42–44], and (4) the
Self-Perceived Burden from Informal Care [45].
Sample size
For the original calculation of sample size, we refer to our
study protocol [15]. As a result of the aforementioned
changes in the randomization procedure, we removed the
correction factor to adjust for a cluster effect, yielding an
aimed total sample size of 84 patients.
Statistical analysis
Data were stored and analyzed in the Radboud university
medical center, Nijmegen, the Netherlands, using SPSS
Software (IBM Corp. Released 2011. IBM SPSS Statistics
for Windows, Version 20.0. Armonk, NY: IBM Corp).
Observed values were reported as the mean and standard
deviation (SD) for continuous variables, and the number
and percentage for categorical variables.
The null hypothesis for this study was that there would be
no difference in patient-experienced symptom burden be-
tween the intervention and control groups. To test this hy-
pothesis, for all outcomes, a mixed model with a random
intercept for “Patient” was used to accommodate the
repeated measurements over time. The dependent variable
was the relevant outcome, at any time after T0. For scale
variables, a linear mixed model was used, while for
dichotomous outcomes, a generalized mixed model with a
logit-link function was used. To identify the best model, a
series of models was tested. Starting from the simplest
model, each subsequent model was extended step by step
until further extensions showed non-significant improvement.
The simplest model had only the Experimental condition
(i.e., “group”: intervention or control) and the measurement
of the outcome variable at T0 (“score at baseline”) as the
independent variables. The next step added Time as an
independent variable. After that, the interaction between
Experimental condition and Time (“group*time”) was
considered.
By using mixed models, every available observation
contributes to the modeling of the relation between outcome
and variables. As a result of this approach, missing data did
not result in exclusion of participants from analyses.
Statistical software R, version 3.0.1, was used in com-
bination with the lmer procedure from the lme4 library
for the mixed modeling analyses.
Results
A total of 957 patients were screened. We excluded patients
who (1) did not meet the inclusion criteria (n = 511); (2) were
not approached for participation for other reasons (n = 202);
or (3) were not willing to participate (n = 167). Thus, a total
of 77 participants gave informed consent and were enrolled
in the study. Of these participants, three did not complete
the baseline measurement. Consequently, 74 participants
were randomized to either the intervention group (n = 38) or
the control group (n = 36). A total of 32 participants (42%)
completed the study. All other participants prematurely
ended this study for several reasons, mostly related to death
or deteriorating condition (Fig. 1). The attrition rates were
relatively high in both groups; 61% and 53% of participants
in the intervention and control group, respectively, stopped
contributing data during the course of the study. These rates
did not differ between groups (P= 0.64). Sensitivity analyses
on the attrition rates in relation to baseline measurements of
participants showed a significant correlation between base-
line scores on TDS, HADS-anxiety, and HADS-depression
and attrition rates for participants from the control group.
The effect of this on the study outcomes was mitigated by
including baseline scores as independent variables in the
regression models.
Demographic baseline characteristics are shown in
Table 1. All 74 participants were analyzed for the primary
outcome. Furthermore, 71 participants had an informal
caregiver who gave informed consent and was enrolled in
the study.
Due to financial and time constraints this study was
ended after 45 months before the calculated sample size
was reached.
Symptom burden
At baseline, the mean observed TDS in the intervention
group was almost 7 points higher (31.03 ± 17.21) than that
of the control group (24.33 ± 14.54). Over the study period,
the control group showed a slight decline in the mean ob-
served TDS. The intervention group also showed a decline
in the mean observed TDS during the first 8 weeks of the
study; however, in the last 4 weeks, the mean TDS increased
almost 9 points to 36.62 (±20.14) at week 12, compared to
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22.38 (±11.27) in the control group (Table 2). The adjusted
TDS scores became significantly higher in the intervention
group, indicating a growing symptom burden in this group
over time compared to the control group (Fig. 2). When
testing specific points in time, this difference reached signifi-
cance at week 12 (adjusted difference at week 12: 6.90; 95%
CI, 0.17 to 13.63; P= 0.04; Table 3).
The mean observed HADS-anxiety scores in the con-
trol group declined somewhat during the first 4 weeks of
the study (from 6.22 ± 3.91 to 5.23 ± 3.41) and thereafter
remained rather stable. Within the intervention group,
the mean observed anxiety scores were relatively stable
during the first 8 weeks of the study, but increased
between week 8 and week 12 from 7.11 (±3.39) to 8.46
(±4.25). Within the intervention group, the mean ob-
served HADS-depression scores remained stable during
the study period. The mean observed depression scores
declined in the control group during the first 8 weeks
(from 6.49 ± 4.57 to 5.76 ± 3.92); however, over the last
4 weeks, depression scores increased to 7.00 (±4.95) at
week 12 (Table 2). The adjusted anxiety scores were sig-
nificantly higher in the intervention group than in the
control group (estimate effect: 1.40; 95% CI, 0.14 to 2.66;
P = 0.03). The depression scores did not differ between
the two groups (estimate effect: 0.30; 95% CI, −1.39 to
1.99; P = 0.73; Table 3).
Fig. 1 Screening and participants, *More than one reason may apply
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Secondary and other study outcomes
The mean number of unmet needs did not differ between
the intervention and control groups (estimate effect: –0.01;
95% CI, −0.07 to 0.04; P = 0.67). Additionally, the number
of participants having at least one unmet need did not differ
between the groups (OR: 0.79; 95% CI, 0.19 to 2.92; P =
0.66). On all three subscales of the NCQ for continuity of
care, i.e., personal continuity (estimate effect: 0.15; 95% CI,
−0.09 to 0.38; P = 0.22), team continuity (estimate effect:
0.16; 95% CI, −0.20 to 0.51; P = 0.39), and cross-boundary
continuity (estimate effect: 0.29; 95% CI, −0.08 to 0.67;
P = 0.13), there were no differences between groups. Finally,
the mean number of hospital admissions during the
study period did not differ between the intervention
group (0.47) and the control group (0.38; P = 0.60).
Study outcome measures regarding GP contacts and
complex interventions did not statistically differ be-
tween both groups. The mean satisfaction scores after
the first two teleconsultations were high for both the
participants (90.4 ± 8.2 and 89.4 ± 9.7) and the SPCT
members (87.0 ± 7.1 and 85.5 ± 15.2).
When comparing the number of informal caregivers
with a high perceived burden (defined as the upper third
of the group), there was a trend towards a lower propor-
tion of informal caregivers with a high perceived burden
in the intervention group (estimate effect: −2.24; 95% CI,
−5.24 to 0.02; P = 0.05).
Discussion
Main results
We found a difference in reported symptom burden be-
tween home-dwelling patients with advanced cancer receiv-
ing palliative care “as usual” and patients who additionally
had weekly teleconsultations with a hospital-based SPCT.
Therefore, we can reject our null hypothesis, which stated
that there would be no difference in patient-experienced
symptom burden between the intervention group and the
control group. Contrary to our expectations, this additional
intervention led to a higher reported symptom burden in
the intervention group than in the control group. The num-
ber of unmet needs, experienced continuity of care, and re-
ported hospital admissions did not differ between groups.
Comparison with the literature
To the best of our knowledge, this is the first RCT to
show that, despite difficulties in recruitment, technical
challenges, and relatively high drop-out rates, it is possible
to perform an RCT on telemedicine, which can be consid-
ered a complex intervention, in palliative care [46].
We found an observed mean TDS ranging from 21.4
to 36.6. This is comparable to other studies reporting
ESAS scores from patients with advanced cancer visiting
outpatient clinics [47–49], although higher scores have
been reported [50].
While the TDS in the control group remained relatively
stable during the study period, the TDS of the intervention
group increased. For both the observed and the adjusted
TDS, this increase was of more than 4 points, indicating a
clinically relevant deterioration according to Hui et al. [49].
This deterioration seems to be in contrast with earlier
research in which video technologies did not affect symptom
burden or even led to a possible improvement in clinical out-
comes [21, 25]. On the other hand, the adjusted difference
between both groups at week 12 was less than 8 points,
which is the minimum clinically important difference stated
in the power calculation of our study protocol [15]. There-
fore, and given the relatively wide confidence intervals of the
Table 1 Baseline characteristics of the participants (n = 74)
Intervention
group (n = 38)
Control group
(n = 36)
Demographics
Age, mean (SD), years 62.3 (9.0) 61.9 (10.6)
Female, n (%) 11 (29) 14 (39)
Diagnosis, n (%)
Urogenital cancer 13 (34) 15 (42)
Gastro-intestinal cancer 6 (16) 5 (14)
Hepatobiliary and pancreatic cancer 4 (11) 5 (14)
Lung cancer 6 (16) 2 (6)
Head and neck cancer 3 (8) 5 (14)
Breast cancer 3 (8) 0 (0)
Skin cancer 0 (0) 1 (3)
Other type of cancer 3 (8) 3 (8)
Marital status, n (%)
Married/permanent relationship 27 (71) 29 (81)
Divorced 5 (13) 1 (3)
Single 4 (11) 5 (14)
Widow(er) 2 (5) 1 (3)
Having one or more children, n (%) 32 (84) 30 (83)
Living situation, n (%)
Together with partner and/or children 28 (74) 29 (81)
Alone 9 (24) 6 (17)
Other living situation 1 (3) 1 (3)
Household, mean number of persons (SD) 2.0 (0.9) 2.0 (0.6)
Highest educational level, n (%)
No education/primary school 1 (3) 3 (8)
Lower vocational education 10 (26) 7 (19)
Lower general secondary education 4 (11) 8 (22)
Intermediate vocational education 11 (29) 7 (19)
Higher general secondary education/
pre-university education
3 (8) 2 (6)
Higher professional education/university 9 (24) 9 (25)
Percentages may not add to 100% due to rounding
SD Standard deviation
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adjusted difference in TDS, the clinical relevance of
the difference in TDS should be interpreted with
proper caution.
The higher reported symptom burden found in this
study might be partially explained by the participant’s
perceptions of symptoms. Participants in the intervention
group received weekly attention for their (potential)
symptoms. This might have led to a higher awareness of
symptoms among participants, leading to a worsening
symptom experience. This phenomenon is referred to as
the “nocebo effect” [51]. In a review on this topic,
Häuser et al. [51] state that patients are “highly receptive
to negative suggestion, particularly in situations perceived
as existentially threatening”. This negative suggestion
includes focusing one’s attention towards the presence
of particular symptoms. The “nocebo effect” may be
avoided by adapting the frequency and timing of the
teleconsultations to the actual needs of the individual
patient.
Another explanation for our findings might be the
differential recall bias among participants. For partici-
pants in the intervention group, the reported symptom
burden was strongly related to the content of their
weekly teleconsultations. As a result, their symptom
burden may have been registered more precisely,
possibly leading to higher symptom scores.
Table 2 Observed values at baseline and weeks 4, 8, and 12
Group Baseline Week 4 Week 8 Week 12
ESAS
TDS, mean (SD) (0–90) Intervention 31.03 (17.21)
n = 38
30.68 (19.58)
n = 22
27.73 (15.87)
n = 15
36.62 (20.14)
n = 13
Control 24.33 (14.54)
n = 36
24.17 (13.79)
n = 27
22.20 (10.89)
n = 20
22.38 (11.27)
n = 16
HADS
Anxiety, mean (SD) (0–21) Intervention 7.24 (4.70)
n = 38
7.48 (4.19)
n = 23
7.11 (3.39)
n = 16
8.46 (4.25)
n = 13
Control 6.22 (3.91)
n = 36
5.23 (3.41)
n = 26
4.71 (3.08)
n = 21
5.06 (3.21)
n = 16
Depression, mean (SD) (0–21) Intervention 7.66 (3.87)
n = 38
7.45 (4.82)
n = 23
7.31 (4.45)
n = 16
7.85 (5.10)
n = 13
Control 6.49 (4.57)
n = 36
6.25 (4.16)
n = 26
5.76 (3.92)
n = 21
7.00 (4.95)
n = 16
PNPC-sv
Number of unmet needs, mean (SD) (0–32) Intervention 3.94 (5.68)
n = 37
2.07 (3.82)
n = 23
1.31 (3.48)
n = 16
2.02 (3.88)
n = 13
Control 2.92 (4.36)
n = 36
2.57 (3.75)
n = 25
1.42 (2.60)
n = 17
2.80 (5.21)
n = 15
NCQ
Personal continuity, mean (SD) (6–30) Intervention 24.33 (3.76)
n = 36
24.52 (3.10)
n = 23
24.73 (3.26)
n = 15
24.38 (3.55)
n = 13
Control 22.81 (4.43)
n = 33
23.00 (3.43)
n = 25
23.28 (5.33)
n = 18
21.92 (4.27)
n = 13
Team continuity (within hospital), mean (SD) (4–20) Intervention 14.20 (3.26)
n = 30
15.89 (2.27)
n = 18
15.75 (2.01)
n = 12
14.60 (3.24)
n = 10
Control 15.12 (3.15)
n = 31
15.59 (2.92)
n = 17
15.42 (2.61)
n = 12
13.73 (2.45)
n = 11
Cross-boundary continuity, mean (SD) (4–20) Intervention 15.83 (3.09)
n = 24
16.56 (3.01)
n = 18
14.20 (2.78)
n = 15
16.59 (2.98)
n = 13
Control 15.16 (3.13)
n = 25
15.35 (2.57)
n = 18
14.10 (4.25)
n = 13
14.33 (3.20)
n = 9
EDIZ
Total score, mean (SD) (9–45) Intervention 15.78 (5.87)
n = 36
14.54 (7.09)
n = 21
16.09 (8.39)
n = 16
15.95 (8.25)
n = 12
Control 15.54 (6.46)
n = 35
17.45 (8.39)
n = 25
14.74 (5.88)
n = 19
15.00 (7.10)
n = 14
SD standard deviation, ESAS Edmonton Symptom Assessment System, TDS Total Distress Score, HADS Hospital Anxiety and Depression Scale, PNPC-sv Problems
and Needs in Palliative Care-Short Version, NCQ Nijmegen Continuity Questionnaire, EDIZ self-perceived burden from informal care
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Strengths and limitations
An important strength of this study is that we have
systematically screened a large group of patients for partici-
pation in this trial. Despite considerable difficulties in re-
cruitment, the intended sample size was nearly reached,
although over a longer period of time and with adjusted
inclusion criteria. Finally, this is the first completed RCT on
telemedicine in palliative care with outcome measures that
are clinically relevant and relate directly to patient care and
experienced quality of life. This study also has some limita-
tions. First, a considerable group of patients who were eli-
gible for participation in this trial were not approached,
mostly as a result of clinical considerations, which may
have caused non-differential selection bias. Additionally,
the relatively small number of patients who were eventually
approached for participation might also reflect that offering
teleconsultations in the context of a randomized study
might not fit the needs of palliative care patients. Second,
the attrition rate in this study was relatively high and attri-
tion may depend on the clinical condition of participants.
Although in our statistical models we have corrected for
baseline measurements (i.e., the clinical condition of partic-
ipants at the start of the study), study outcomes may have
been influenced by participants’ worsening clinical condi-
tion during the study. Third, the participants sometimes
had difficulty adequately completing the questionnaires as a
result of their varying clinical conditions. This might have
led to information bias, although likely non-differential.
Fourth, the outcome measure “place of death” was de-
scribed in the study protocol, however, it was not included
in the information request at the patient’s GP; thus, this
study outcome is missing. Fifth, two amendments had to be
made to the study protocol to improve the recruitment
rates. As a result of widening the inclusion criteria of this
study, the study population may have become more hetero-
geneous, which may have led to a dilution of the effect of
the intervention. Finally, the involvement of GPs in this
study was less than expected; therefore, the participants
were not recruited by their GP but were instead recruited
at the outpatient clinic of the SPCT, probably leading to
higher levels of specialist care in both groups, which may
have positively affected symptom scores.
Fig. 2 Adjusted Total Distress Score during the study period
Table 3 Primary outcome measures – mixed models
B (SE) 95% CI P value
Lower limit Upper limit
ESAS-TDS
Intercept 7.26 (3.17)
Groupa −0.66 (3.26) −6.99 5.66 0.84
TDS score at
baseline
0.78 (0.11) 0.57 0.99 <0.001
Timeb 0.12 (0.17) −0.21 0.45 0.48
Group*time 0.63 (0.25) 0.14 1.11 0.01
HADS-A
Intercept 0.54 (0.76)
Groupa 1.40 (0.65) 0.14 2.66 0.03
HADS-A score
at baseline
0.78 (0.09) 0.61 0.95 <0.001
Timeb 0.12 (0.06) 0.01 0.23 0.04
HADS-D
Intercept 1.56 (1.03)
Groupa 0.30 (0.87) −1.39 1.99 0.73
HADS-D score
at baseline
0.70 (0.11) 0.49 0.91 <0.001
Timeb 0.13 (0.08) −0.03 0.29 0.12
B estimate effect, SE standard error, 95% CI 95% confidence interval, ESAS
Edmonton Symptom Assessment System, TDS Total Distress Score, HADS-A
Hospital Anxiety and Depression Scale – Anxiety, HADS-D Hospital Anxiety and
Depression Scale – Depression
aGroup: intervention = 1; control = 0
bTime: week number, baseline = week 0
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Clinical implications
In this study, we introduced a model for teleconsultation in
palliative care that was intended to be proactive and was
mainly supply driven. Teleconsultations were scheduled on
a weekly basis for a period of 3 months, irrespective of the
actual needs of the patient regarding the timing and
frequency of these teleconsultations. This model was shown
to be ineffective in reducing experienced symptom burden,
even though patients and caregivers showed a high degree
of satisfaction. Therefore, we propose focusing on care
models that are patient-tailored and demand-driven, i.e.,
patients themselves indicate when they are in need of
palliative care (tele)consultations. This model could prevent
a possible excess of medical care regarding palliative care,
death, and dying. At the same time, to avoid a rather react-
ive palliative care approach, patients should be provided
tools and support to guide them in proactively contacting
their caregivers when problems arise.
Conclusions
Telemedicine is emerging in all fields of medicine, includ-
ing palliative care. Despite promising earlier research, the
present study shows that telemedicine does not necessarily
lead to a better quality of advanced cancer care. Indeed, the
use of telemedicine might create a situation in which
patients experience a higher symptom burden, despite high
degrees of satisfaction. Future research and care models
should therefore explore the beneficial as well as the poten-
tially harmful aspects of teleconsultations within advanced
cancer care, thereby focusing on (1) ways to optimize
multidisciplinary care via teleconsultations, (2) the appro-
priate timing and frequency of palliative care teleconsulta-
tions for patients with advanced cancer and other groups of
vulnerable patients, (3) possibilities for patient-tailored,
demand-driven teleconsultations, and (4) the potential
impact of technology as such on the patient’s sense of well-
being. These issues should be adequately addressed, both in
future research and in implementation trajectories regard-
ing the use of telemedicine in palliative home care.
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